Pazopanib Observational Study (PRINCIPAL) - A prospective observational study to capture real world treatment patterns and determine treatment outcomes in patients with advanced or metastatic renal cell carcinoma (RCC) receiving pazopanib.

Trial Profile

Pazopanib Observational Study (PRINCIPAL) - A prospective observational study to capture real world treatment patterns and determine treatment outcomes in patients with advanced or metastatic renal cell carcinoma (RCC) receiving pazopanib.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRINCIPAL
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 12 Jul 2017 Status changed from recruiting to completed.
    • 02 Feb 2017 Status changed from active, no longer recruiting to recruiting.
    • 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top